NASDAQ Stocks Earnings Forecast: NVGN, RRGB

Los Angelas, CA -- (SBWIRE) -- 02/19/2013 -- Novogen Limited (ADR) (NASDAQ:NVGN) shares got a boost on Tuesday after a study showed that its new anti-ovarian cancer drug was highly effective against ovarian cancer stem cells.

The study has conclusively proved that the drug, CS-6, is not only effective against cancer cells but can also fight cancer stem cells.

This is a major breakthrough since cancer stem cells have been identified in a range of cancers including ovarian, brain cancers and leukaemia and are almost completely resistant to radiotherapy and standard anti-cancer drugs.

The study was done by Mazor Oncology, a spin off company of Yale University that has expertise in cancer stem cells.

In fact other studies have found that ovarian cancer stem cells are the source of ovarian cancer recurrence. So the dual action of CS-6 is all the more remarkable since it marks the effectiveness of the drug as a comprehensive chemotherapy.

Targeting the ovarian cancer stem cells represent a critical approach to prevent recurrence, the main cause of mortality in patients with ovarian cancer.

The CS-6 belongs to a new class of drug candidates known as super benzopyrans displaying potent anti-cancer activity.

Shares of NVGN are up 143%.

Can NVGN Continue To Move Higher? Find Out Here

Red Robin Gourmet Burgers Inc., (NASDAQ:RRGB) trading at $43.66 gained $7.21 or 19.78% on a volume of 480,486 shares.

Red Robin Gourmet Burgers, Inc. today reported positive financial results for the 13 and 53 weeks ended December 30, 2012.

Financial Highlights for the 13 Weeks Ended December 30, 2012, Compared to the 12 Weeks Ended December 25, 2011:

Earnings per diluted share were $0.45, compared to fiscal fourth quarter 2011 earnings per diluted share of $0.20, while adjusted earnings per diluted share were $0.59, compared to $0.28 in the fiscal fourth quarter a year ago.

Total revenues also increased 16.8% to $240.7 million; Company-owned comparable restaurant revenues increased 1.4% on a 13-week comparable basis.

For the 53 weeks ended December 30, 2012, GAAP net income was $28.3 million, or $1.93 per diluted share, compared to $20.6 million, or $1.34 per diluted share, for the 52 weeks ended December 25, 2011.

What Should Investors Do With RRGB Now? Find Out Here

DISCLAIMER:
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com